Daily Hong Kong Stock Market News Express (Friday, September 27)

Individual Stock News

China Life Insurance (02628.HK): Completed the issuance of capital replenishment bonds with a total amount of 35 billion yuan.
New World Development (00017.HK): Zheng Zhigang has submitted his resignation as the company's CEO, and Ma Shaoxiang has been appointed as the new CEO.
HSBC Holdings (00005.HK): Completed the issuance of Hong Kong's first private institutional digital bonds, totaling 1 billion Hong Kong dollars.
Junshi Biosciences (01877.HK): JS125 has received the drug clinical trial approval notification.
Country Garden Holdings (00053.HK): Released annual performance for the year ending June 30, 2024, with revenue of 25.786 billion Hong Kong dollars, a year-on-year increase of 17%; net profit of 3.581 billion Hong Kong dollars, a year-on-year increase of 4%. Mainly driven by strong sales of residential projects in Singapore and increased revenue from the hotel and leisure division.
Ascletis (01167.HK): The new drug clinical trial application for the self-developed Pan-KRAS inhibitor AB-23E73 has been approved in China

Source: USHK News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.